WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 527461
CAS#: 60607-34-3
Description: Oxatomide is an H1 receptor antagonist, possessing antiserotonergic actions.
MedKoo Cat#: 527461
Name: Oxatomide
CAS#: 60607-34-3
Chemical Formula: C27H30N4O
Exact Mass: 426.242
Molecular Weight: 426.564
Elemental Analysis: C, 76.03; H, 7.09; N, 13.13; O, 3.75
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Oxatomide
IUPAC/Chemical Name: 3-[3-(4-Benzhydrylpiperazin-1-yl)propyl]-1H-benzimidazol-2-one
InChi Key: BAINIUMDFURPJM-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
SMILES Code: O=C1N(CCCN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)C5=CC=CC=C5N1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 426.564 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Tobe M, Tsuboi K, Hasegawa F, Fujiwara N, Inoue Y, Isobe M, Isobe Y. Synthesis and biological evaluation of novel orally available 1-phenyl-6-aminouracils containing dimethyldihydrobenzofuranol structure for the treatment of allergic skin diseases. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1292-5. doi: 10.1016/j.bmcl.2016.01.019. Epub 2016 Jan 8. PubMed PMID: 26786694.
2: Yoshida K, Ito M, Matsuoka I. P2X7 receptor antagonist activity of the anti-allergic agent oxatomide. Eur J Pharmacol. 2015 Nov 15;767:41-51. doi: 10.1016/j.ejphar.2015.10.002. Epub 2015 Oct 16. PubMed PMID: 26463039.
3: Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, Perina L, Hazell L, Moretti U, Sturkenboom M, Garbe E, Pariente A, De Ponti F. The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. Drug Saf. 2016 Jan;39(1):59-68. doi: 10.1007/s40264-015-0353-1. PubMed PMID: 26446144; PubMed Central PMCID: PMC4712251.
4: Curtin Whelan L, Geary M, Sweetman P. Development and validation of a rapid liquid chromatographic method for the determination of oxatomide and its related impurities. J Chromatogr Sci. 2014 Nov-Dec;52(10):1267-72. doi: 10.1093/chromsci/bmt209. Epub 2014 Jan 27. PubMed PMID: 24474428.
5: Hashem FM, Mostafa M, Shaker M, Nasr M. In Vitro and In Vivo Evaluation of Oxatomide β -Cyclodextrin Inclusion Complex. J Pharm (Cairo). 2013;2013:629593. doi: 10.1155/2013/629593. Epub 2012 Dec 6. PubMed PMID: 26555988; PubMed Central PMCID: PMC4595936.
6: Antoniazzi S, Cattaneo D, Perrone V, Carnovale C, Cherubini S, Mugolino MC, Clementi F, Zuccotti G, Clementi E, Radice S. Inflammation and neurological adverse drugs reactions: a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis. Ital J Pediatr. 2012 Mar 30;38(1):11. doi: 10.1186/1824-7288-38-11. PubMed PMID: 22464080; PubMed Central PMCID: PMC3337248.
7: Mizuguchi H, Ono S, Hattori M, Fukui H. Inverse agonistic activity of antihistamines and suppression of histamine H1 receptor gene expression. J Pharmacol Sci. 2012;118(1):117-21. Epub 2011 Dec 21. PubMed PMID: 22186623.
8: Balraj C, Ganesh K, Elango KP. Molecular complexes of ketaconazole and oxatomide with p-chloranil: spectroscopic and spectrofluorimetric studies. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Sep;79(5):1137-44. doi: 10.1016/j.saa.2011.04.033. Epub 2011 May 12. PubMed PMID: 21632281.
9: Shoji N, Asano K, Furuta A, Hirano K, Suzaki H. Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25. PubMed PMID: 21109747.
10: Phan H, Moeller ML, Nahata MC. Treatment of allergic rhinitis in infants and children: efficacy and safety of second-generation antihistamines and the leukotriene receptor antagonist montelukast. Drugs. 2009;69(18):2541-76. doi: 10.2165/9884960-000000000-00000. PubMed PMID: 19943707.
11: Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. Epub 2008 Apr 29. PubMed PMID: 18446005.
12: She X, Wu L, Wei H, Liu W, Chen Y. Determination of oxatomide in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Biomed Chromatogr. 2008 Jul;22(7):746-52. doi: 10.1002/bmc.992. PubMed PMID: 18348338.
13: Buyse GM, Goemans N, Henricson E, Jara A, van den Hauwe M, Leshner R, Florence JM, Mayhew JE, Escolar DM. CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy. Eur J Paediatr Neurol. 2007 Nov;11(6):337-40. Epub 2007 Apr 24. PubMed PMID: 17459739.
14: Ebihara S, Kurachi H, Watanabe Y. A simple preparation method for mouse eosinophils and their responses to anti-allergic drugs. Inflamm Res. 2007 Mar;56(3):112-7. PubMed PMID: 17406808.
15: Park YS, Auo HJ, Jeon EJ, Chang KH, Lee SK, Lee DH. Effect of inhibitor of tumor necrosis factor-alpha and oxatomide on immune mediated otitis media. Laryngoscope. 2006 Sep;116(9):1642-6. PubMed PMID: 16954996.
16: Kakutani C, Ogino S, Ikeda H, Enomoto T. [Comparison of clinical efficacy and cost-quality of antihistamines in early treatment for Japanese cedar pollinosis]. Arerugi. 2006 May;55(5):554-65. Japanese. PubMed PMID: 16883093.
17: Ujiie H, Shimizu T, Natsuga K, Arita K, Tomizawa K, Shimizu H. Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines. Clin Exp Dermatol. 2006 Jul;31(4):588-9. PubMed PMID: 16716168.
18: Pandeeswaran M, Elango KP. Solvent effect on the charge transfer complex of oxatomide with 2,3-dichloro-5,6-dicyanobenzoquinone. Spectrochim Acta A Mol Biomol Spectrosc. 2006 Dec;65(5):1148-53. Epub 2006 Feb 20. PubMed PMID: 16488184.
19: Malheiro D, Cadinha S, Rodrigues J, Vaz M, Castel-Branco MG. Nimesulide-induced fixed drug eruption. Allergol Immunopathol (Madr). 2005 Sep-Oct;33(5):285-7. PubMed PMID: 16287549.
20: Parant F, Moulsma M, Gagnieu MC, Lardet G. Hydroxyzine and metabolites as a source of interference in carbamazepine particle-enhanced turbidimetric inhibition immunoassay (PETINIA). Ther Drug Monit. 2005 Aug;27(4):457-62. PubMed PMID: 16044102.
